Dianthus (DNTH) Therapeutics announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. Initial top-line results from the MaGic trial are anticipated in September 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
- Short Report: Bears focus on crypto space, boost bets on CleanSpark, Mara
- Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
- Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating
- Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress